{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51.5","upperLimit":"70.9","value":"61.5"},{"groupId":"OG001","lowerLimit":"42.2","upperLimit":"70.7","value":"56.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"51"}],"units":"Participants"}],"description":"DCR was defined as the percentage of participants who had a CR (disappearance of all target and non-target lesions), PR (at least a 30% decrease in the sum of diameters of target and non-target lesions), or Stable Disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \\[PD was at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm, OR unequivocal progression for non-target lesions, OR appearance of one or more new lesions.\\]). CR, PR, and SD were evaluated per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded central imaging vendor. Participants with missing data were considered as participants whose disease was not under control. The percentage of participants who experienced a confirmed CR, PR, or SD is reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with previously systemically treated HCC received a pembrolizumab 200 mg IV infusion on Day 1 of each 3-week cycle for up to 35 administrations. Participants who stopped pembrolizumab as a result of obtaining a confirmed complete response (CR) or those who stopped after receiving 35 trial treatments were eligible for an additional 17 trial treatments (approximately an additional 1 year of treatment) after progressive disease if they met the criteria for re-treatment.","id":"OG000","title":"Cohort 1: HCC-Prior Systemic Therapy With Sorafenib"},{"description":"Participants with HCC who had not received treatment for systemic disease received a pembrolizumab 200 mg IV infusion on Day 1 of each 3-week cycle for up to 35 administrations. Participants who stopped pembrolizumab as a result of obtaining a confirmed complete response (CR) or those who stopped after receiving 35 trial treatments were eligible for an additional 17 trial treatments (approximately an additional 1 year of treatment) after progressive disease if they met the criteria for re-treatment.","id":"OG001","title":"Cohort 2: HCC-Systemic Therapy Naïve"}],"paramType":"NUMBER","populationDescription":"All participants who received at least one dose of study treatment during the first course of therapy.","reportingStatus":"POSTED","timeFrame":"Up to approximately 34 months for Cohort 1 and up to approximately 28 months for Cohort 2","title":"Disease Control Rate (DCR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}